Active substance
Metamfetamine
- US FDA 8
- US price lines 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DESOXYN | 5MG | tablet · oral | AJENAT PHARMS | Prescription | 31 Dec 1943 |
| METHAMPHETAMINE HYDROCHLORIDE | 5MG | tablet · oral | DR REDDYS LABS SA | Prescription | 21 Apr 2010 |
| METHAMPHETAMINE HYDROCHLORIDE | 5MG | tablet · oral | HIKMA PHARMS | Prescription | 17 Nov 2015 |
| DESOXYN | 10MG; 5MG; 15MG | tablet, extended release · oral | AJENAT PHARMS | Discontinued | 31 Dec 1943 |
| METHAMPHETAMINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | REXAR | Discontinued | 19 Jan 1976 |
| METHAMPHETAMINE HYDROCHLORIDE | 5MG | tablet · oral | ABLE | Discontinued | 25 Feb 2004 |
| METHAMPEX | 10MG | tablet · oral | TEVA | Discontinued | |
| METHAMPHETAMINE HYDROCHLORIDE | 5MG | tablet · oral | TEVA | Discontinued |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | METHAMPHETAMINE 5 MG TABLET | $5.0978 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 24 Sep 2024 DESOXYN — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.